Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients with early-stage, slow-progressing mild cognitive impairment—a condition that can progress to Alzheimer’s.
Go to Source
https://medicalxpress.com/rss-feed/